company background image
KZA

Kazia TherapeuticsASX:KZA Stock Report

Last Price

AU$1.10

Market Cap

AU$145.2m

7D

-1.8%

1Y

-21.4%

Updated

20 Jan, 2022

Data

Company Financials +
KZA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

KZA Stock Overview

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs.

Price History & Performance

Summary of all time highs, changes and price drops for Kazia Therapeutics
Historical stock prices
Current Share PriceAU$1.10
52 Week HighAU$1.88
52 Week LowAU$1.05
Beta2.56
1 Month Change-0.45%
3 Month Change-26.17%
1 Year Change-21.43%
3 Year Change129.17%
5 Year Change29.41%
Change since IPO-67.65%

Recent News & Updates

Nov 03
We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned

We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned

The performance at Kazia Therapeutics Limited ( ASX:KZA ) has been quite strong recently and CEO James Garner has...

Sep 23
We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth

We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

KZAAU BiotechsAU Market
7D-1.8%-3.9%-1.7%
1Y-21.4%1.2%7.7%

Return vs Industry: KZA underperformed the Australian Biotechs industry which returned 1.2% over the past year.

Return vs Market: KZA underperformed the Australian Market which returned 7.7% over the past year.

Price Volatility

Is KZA's price volatile compared to industry and market?
KZA volatility
KZA Average Weekly Movement7.6%
Biotechs Industry Average Movement9.1%
Market Average Movement8.5%
10% most volatile stocks in AU Market15.3%
10% least volatile stocks in AU Market3.6%

Stable Share Price: KZA is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: KZA's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1994n/aJames Garnerhttps://www.kaziatherapeutics.com

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer.

Kazia Therapeutics Fundamentals Summary

How do Kazia Therapeutics's earnings and revenue compare to its market cap?
KZA fundamental statistics
Market CapAU$145.24m
Earnings (TTM)-AU$8.42m
Revenue (TTM)AU$15.18m

9.6x

P/S Ratio

-17.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KZA income statement (TTM)
RevenueAU$15.18m
Cost of RevenueAU$0
Gross ProfitAU$15.18m
ExpensesAU$23.60m
Earnings-AU$8.42m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.064
Gross Margin100.00%
Net Profit Margin-55.47%
Debt/Equity Ratio0.0%

How did KZA perform over the long term?

See historical performance and comparison

Valuation

Is Kazia Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: KZA (A$1.1) is trading below our estimate of fair value (A$34.78)

Significantly Below Fair Value: KZA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: KZA is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: KZA is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KZA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KZA is good value based on its PB Ratio (3.8x) compared to the AU Biotechs industry average (4.5x).


Future Growth

How is Kazia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

68.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KZA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: KZA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: KZA's is expected to become profitable in the next 3 years.

Revenue vs Market: KZA's revenue (52.4% per year) is forecast to grow faster than the Australian market (4.9% per year).

High Growth Revenue: KZA's revenue (52.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: KZA's Return on Equity is forecast to be very high in 3 years time (67%).


Past Performance

How has Kazia Therapeutics performed over the past 5 years?

-1.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KZA is currently unprofitable.

Growing Profit Margin: KZA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KZA is unprofitable, and losses have increased over the past 5 years at a rate of 1.3% per year.

Accelerating Growth: Unable to compare KZA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KZA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (48.2%).


Return on Equity

High ROE: KZA has a negative Return on Equity (-22.25%), as it is currently unprofitable.


Financial Health

How is Kazia Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: KZA's short term assets (A$29.4M) exceed its short term liabilities (A$8.3M).

Long Term Liabilities: KZA's short term assets (A$29.4M) exceed its long term liabilities (A$11.9M).


Debt to Equity History and Analysis

Debt Level: KZA is debt free.

Reducing Debt: KZA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KZA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if KZA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Kazia Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KZA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KZA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KZA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KZA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KZA's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average management tenure


CEO

James Garner (48 yo)

5.92yrs

Tenure

AU$1,132,636

Compensation

Dr. James Garner, MA, MBA, MBBS, BSC (Hons), MAICD, has been the Chief Executive Officer, Managing Director and Executive Director of Kazia Therapeutics Limited (formerly Novogen Limited) since February 1,...


CEO Compensation Analysis

Compensation vs Market: James's total compensation ($USD817.85K) is above average for companies of similar size in the Australian market ($USD290.00K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: KZA's management team is seasoned and experienced (5.1 years average tenure).


Board Members

Experienced Board: KZA's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: KZA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.7%.


Top Shareholders

Company Information

Kazia Therapeutics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Kazia Therapeutics Limited
  • Ticker: KZA
  • Exchange: ASX
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$145.241m
  • Shares outstanding: 132.04m
  • Website: https://www.kaziatherapeutics.com

Location

  • Kazia Therapeutics Limited
  • Three International Towers
  • Level 24
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/20 15:48
End of Day Share Price2022/01/20 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.